Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B

Bui, Hoang Huu; Nguyen, Suong Thi-Bang; Phan, Sang The; Nguyen, Khue Minh; Nguyen, Chuong Dinh

doi:10.1007/s10620-023-08143-5

“…In a study to distinguish LSM ≥7 kPa in Vietnam, cut-offs of 0.5 and 1.8 were obtained for APRI and FIB-4, respectively. 12 In patients with liver elastography results ≥9 kPa in Egypt, the cut-offs were at 0.256, 0.74, and 0.8 for APRI, FIB-4, and AAR, respectively. 27 For predicting Knodell histologic activity index (HAI) ≥F2 results, APRI and FIB-4 had the best cut-offs at 0.9 and 0.35, respectively.…”

Section: Discussionmentioning

confidence: 95%

“…In diagnosing LSM ≥8 kPa, the value appeared lower in this study (0.311) compared to other studies, regardless of the dependent variable groupings. 11 , 12 , 15 From the various reviews that have been done, the possibility of this result could occur because the baseline data on platelet count in our population was considered to be the highest, with an average of 237.2 (×10 9 /L). A high platelet count causes the distribution of APRI values to be lower, lowering the further obtained cut-off.…”

Section: Discussionmentioning

confidence: 99%

“…A high platelet count causes the distribution of APRI values to be lower, lowering the further obtained cut-off. Zou, 15 Jekarl, 11 and Bui 12 had median platelet counts of 155, 185, and 206, respectively, resulting in a decreasing trend of APRI cut-offs of 1.06, 0.9, and 0.569, respectively.…”

Section: Discussionmentioning

confidence: 99%

“… 5 – 18 In several previous studies, M2BPGi helped to diagnose liver fibrosis in a CHB population 6 , 11 and it could be used as a single predictor variable to diagnose liver fibrosis grade. 12 , 13 This marker could also complement and be used with other modalities. 14 , 15 The most accurate non-invasive methods to assess fibrosis are liver stiffness measurements (elastography), followed by several scoring methods such as the AST-to-platelet ratio index (APRI), the fibrosis index based on four factors (FIB-4), and the AST-to-ALT ratio (AAR).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis in Chronic Hepatitis B Patients: A Stepwise Diagnostic Analysis

Bestari,

Haryono,

Wijaya

et al. 2024

F1000Res

0

View full text Add to dashboard Cite

Abstract* Background The level of liver fibrosis is the basis for the treatment of chronic hepatitis B (CHB), and it is necessary to adapt non-invasive liver fibrosis modalities. We aimed to investigate the use of M2BPGi as a single or combined diagnostic modality for liver fibrosis in CHB patients through a stepwise diagnostic analysis. Methods Cross-sectional data were taken from patients between October 2021 and August 2022. Demographic data, blood profile, liver function, and liver stiffness were measured in CHB patients over 18 years old, willing to take part in the research, and had complete data. APRI, FIB-4, and AAR were calculated using the well-known formulas. Serum M2BPGi-levels were converted into a cut-off index (COI). The patients were divided into low-risk (LR) and high-risk fibrosis (HR) groups. A cut-off for each predictor variable to differentiate between the LR and HR groups was determined. The obtained cut-off was assessed for its association with the grouping of liver elastography results. Models to diagnose the liver stiffness measurement (LSM) ≥8 kPa were created and compared through multivariate and ROC analyses. Results The number of patients that met the inclusion and exclusion criteria was 143 (HR = 65, LR = 78). The cut-off for diagnosing LSM ≥8kPa was 0.311, 0.742, 0.635, and 1.434 for APRI, FIB-4, AAR, and M2BPGi, respectively. This cut-off was significantly associated with the results of the HR and LR groupings. A multivariate analysis found that FIB4, AAR, and M2BPGi added significantly to the model. Statistically, the most optimal use of M2BPGi was combined with FIB-4, with an AUC of 0.835. Conclusions The optimal cut-off of M2BPGi for diagnosing high-risk liver fibrosis in this study was 1.434. M2BPGi should be used with FIB-4 as a diagnostic tool for diagnosing liver fibrosis, especially in the absence of a liver biopsy or elastography.

show abstract

“…Bui et al investigated the efficiency of M2BPGi to differentiate fibrosis stages in a cross-sectional study that included 177 patients with CHB, using fibroscan as a gold standard. The cut-off value for significant fibrosis (F ≥ 2) was 0.79 with an AUROC of 0.77, 67.3% sensitivity and 70% specificity, and for diagnosing cirrhosis (F4) was 1.3 with an AUROC of 0.91, 88% sensitivity and 87.4% specificity [28]. Many blood-based biomarkers, such as M2BPGi, are influenced by necroinflammatory activity.…”

Section: Other Markersmentioning

confidence: 98%

Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients

Bera,

Hamdan-Perez,

Patel

2024

JCM

3

0

View full text Add to dashboard Cite

The aim of this review is to provide updated information on the clinical use of non-invasive serum and imaging-based tests for fibrosis assessment in chronic hepatitis B (CHB) virus infection. In recent years, non-invasive tests (NIT) have been increasingly used to determine eligibility for treatment. Liver biopsy is still considered the gold standard for assessing inflammatory activity and fibrosis staging, but it is an invasive procedure with inherent limitations. Simple serum markers such as APRI and FIB-4 are limited by indeterminate results but remain useful initial tests for fibrosis severity if imaging elastography is not available. Point-of-care US-based elastography techniques, such as vibration-controlled transient elastography or 2D shear wave elastography, are increasingly available and have better accuracy than simple serum tests for advanced fibrosis or cirrhosis, although stiffness cut-offs are variable based on E-antigen status and inflammatory activity. Current NITs have poor diagnostic performance for following changes in fibrosis with antiviral therapy. However, NITs may have greater clinical utility for determining prognosis in patients with CHB that have advanced disease, especially for the development of hepatocellular carcinoma and/or liver decompensation. Algorithms combining serum and imaging NITs appear promising for advanced fibrosis and prognostic risk stratification.

show abstract

Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis: A Stepwise Diagnostic Analysis

Bestari,

Haryono,

Wijaya

et al. 2024

F1000Res

0

View full text Add to dashboard Cite

Abstract* Background The level of liver fibrosis is the basis for the treatment of chronic hepatitis B (CHB), and it is necessary to adapt non-invasive liver fibrosis modalities. We aimed to investigate the use of M2BPGi as a single or combined diagnostic modality for liver fibrosis in CHB patients through a stepwise diagnostic analysis. Methods Cross-sectional data were taken from patients between October 2021 and August 2022. Demographic data, blood profile, liver function, and liver stiffness were measured in CHB patients over 18 years old, willing to take part in the research, and had complete data. APRI, FIB-4, and AAR were calculated using the well-known formulas. Serum M2BPGi-levels were converted into a cut-off index (COI). The patients were divided into low-risk (LR) and high-risk fibrosis (HR) groups. A cut-off for each predictor variable to differentiate between the LR and HR groups was determined. The obtained cut-off was assessed for its association with the grouping of liver elastography results. Models to diagnose the liver stiffness measurement (LSM) ≥8 kPa were created and compared through multivariate and ROC analyses. Results The number of patients that met the inclusion and exclusion criteria was 143 (HR = 65, LR = 78). The cut-off for diagnosing LSM ≥8kPa was 0.311, 0.742, 0.635, and 1.434 for APRI, FIB-4, AAR, and M2BPGi, respectively. This cut-off was significantly associated with the results of the HR and LR groupings. A multivariate analysis found that FIB4, AAR, and M2BPGi added significantly to the model. Statistically, the most optimal use of M2BPGi was combined with FIB-4, with an AUC of 0.835. Conclusions The optimal cut-off of M2BPGi for diagnosing high-risk liver fibrosis in this study was 1.434. M2BPGi should be used with FIB-4 as a diagnostic tool for diagnosing liver fibrosis, especially in the absence of a liver biopsy or elastography.

show abstract

Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B

Cited by 3 publications

References 37 publications

Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis in Chronic Hepatitis B Patients: A Stepwise Diagnostic Analysis

Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis in Chronic Hepatitis B Patients: A Stepwise Diagnostic Analysis

Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients

Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis: A Stepwise Diagnostic Analysis

Contact Info

Product

Resources

About